Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check6 days agoChange DetectedA Scleroderma topic tag was added, and a link to the Genetic and Rare Diseases Information Center was added to Resources. These changes improve discoverability and provide an additional information source for patients without altering the study details.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded Revision: v3.4.2; deleted the Notice about funding lapse and operating status and the previous Revision: v3.4.1.SummaryDifference0.1%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operating status was added, with references to cc.nih.gov and opm.gov. The page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check28 days agoChange DetectedPage changes: the glossary toggle is now shown, and new metadata items appear including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while the previous items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 added to the page; no substantive changes to study content or user-facing information.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section expanded with detailed site listings across multiple states and countries, plus a revision tag v3.3.3.SummaryDifference1%

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.